Literature DB >> 7915721

Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta.

J C Reubi1, U Horisberger, U E Studer, B Waser, J A Laissue.   

Abstract

Somatostatin (SRIH) receptors were identified in human kidneys by in vitro receptor autoradiography using 125I-[Tyr3]octreotide and 125I-[Leu8,D-Trp22,Tyr25]SRIH-28 as radioligands. Characterization of the binding demonstrated a single class of high affinity binding sites with a dissociation constant (Kd) of 0.5 nmol/L. Binding depended on GTP and magnesium and sodium concentrations. SRIH-14, SRIH-28, and octreotide were able to displace the radioligand in the high affinity range, whereas biologically inactive SRIH analogs or unrelated peptides were not. Microscopic localization of these receptors revealed binding over cortical and medullary areas. In the cortex, the receptors were located in the proximal tubules. No SRIH receptors were found in the glomeruli. In the medulla, the receptors were identified in high density in medullary vasa recta. A diffuse labeling of lesser density observed in the remaining medulla corresponded to collecting tubules. The receptor concentration was 32 fmol/mg protein in the renal cortex and 304 fmol/mg protein in the vasa recta. The receptors were undetectable in the rat kidney and are, thus, species dependent. SRIH receptors in the human kidney may be the molecular basis for the actions of SRIH on renal functions and may indicate a therapeutic potential for SRIH analogs in this tissue.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7915721     DOI: 10.1210/jcem.77.5.7915721

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

Review 1.  Octreoscan radioreceptor imaging.

Authors:  Aart J van der Lely; Wouter W de Herder; Eric P Krenning; Dik J Kwekkeboom
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

2.  Cubilin and megalin in radiation-induced renal injury with labelled somatostatin analogues: are we just dealing with the kidney?

Authors:  R Moncayo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10       Impact factor: 9.236

Review 3.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.

Authors:  Jingjing Zhang; Hao Wang; Orit Jacobson; Yuejuan Cheng; Gang Niu; Fang Li; Chunmei Bai; Zhaohui Zhu; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2018-04-13       Impact factor: 10.057

5.  Somatostatin receptor subtype 2-mediated scintigraphy and localization using (99m)Tc-HYNIC-Tyr(3)-octreotide in human hepatocellular carcinoma-bearing nude mice.

Authors:  Yong Li; Jian-Ming Si; Jun Zhang; Jin Du; Fan Wang; Bing Jia
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

6.  Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney.

Authors:  Sunil Bhandari; Neil Watson; Ervine Long; Steve Sharpe; Wenwen Zhong; Shang-Zhong Xu; Stephen L Atkin
Journal:  J Histochem Cytochem       Date:  2008-04-28       Impact factor: 2.479

Review 7.  Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues.

Authors:  Edgar J Rolleman; Marleen Melis; Roelf Valkema; Otto C Boerman; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-14       Impact factor: 9.236

8.  Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney.

Authors:  Edgar J Rolleman; Peter P M Kooij; Wouter W de Herder; Roelf Valkema; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-02       Impact factor: 9.236

9.  Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.

Authors:  Marie C Hogan; Julie A Chamberlin; Lisa E Vaughan; Angela L Waits; Carly Banks; Kathleen Leistikow; Troy Oftsie; Chuck Madsen; Marie Edwards; James Glockner; Walter K Kremers; Peter C Harris; Nicholas F LaRusso; Vicente E Torres; Tatyana V Masyuk
Journal:  Clin J Am Soc Nephrol       Date:  2020-08-25       Impact factor: 8.237

Review 10.  Neuroendocrine tumor theranostics.

Authors:  Yasushi Ichikawa; Noritoshi Kobayashi; Shoko Takano; Ikuma Kato; Keigo Endo; Tomio Inoue
Journal:  Cancer Sci       Date:  2022-04-11       Impact factor: 6.518

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.